Behavioral disturbances are common in patients with dementia. Medical intervention is needed if, for example, these behaviors threaten a patient's safety or jeopardize his or her ability to perform activities of daily living. Typical antipsychotic agents are associated with troublesome adverse effects in the elderly (e.g., anticholinergic effects, extrapyramidal symptoms). Atypical antipsychotics have reduced potential to cause these types of side effects but are not free from side effects. Recently, there has been a greater focus on the use of antidepressants to treat behavioral disturbances in dementia. Among these, selective serotonin reuptake inhibitors have been studied more commonly due to their safety profile in the elderly. Citalopram, in particular, has demonstrated efficacy in improving dementia-related behavioral symptoms.
Get full access to this article
View all access options for this article.
References
1.
DeutschLHBylsmaFWRovnerBWPsychosis and physical aggression in probable Alzheimer's disease. Am J Psychiatry1991; 148: 11591163
2.
Health Care Financing Adminstration: Transmittal 250. Washington, DC: Department of Health and Human Services, 1992
3.
StewartJT. Managing the care of patients with dementia: how to maximize level of functioning and minimize behavior problems. Postgrad Med1991; 90: 4549
4.
LevinHSHighWMGoetheKEThe Neurobehavioral Rating Scale: assessment of the behavioral sequelae of head injury by the clinician. J Neurol Neurosurg Psychiatry1987; 50: 183193
5.
RosenJBurgioLKollarMThe Pittsburgh Agitation Scale: a user-friendly instrument for rating agitation in dementia patients. Am J Geriatr Psychiatry1994; 2: 5259
6.
PollockBGMulsantBHSweetRAProspective cytochrome P450 phenotyping for neuroleptic treatment in dementia. Psychopharmacol Bull1995; 31: 327332
7.
AydFJ. A survey of drug-induced extrapyramidal reactions. JAMA1961; 175: 10541060
8.
JesteDVCaligiuriMPPaulsenJSRisk of tardive dyskinesia in older patients: a prospective study of 266 outpatients. Arch Gen Psychiatry1995; 52: 756765
9.
EvansDAPMaghoubASloanTPA family and population study of the genetic polymorphism of debrisoquin oxidation in a white British population. J Med Genet1980; 17: 102105
10.
BrøsenK. Are pharmacokinetic drug interactions with the SSRIs an issue?Int Clin Psychopharmacol1996; 11(suppl 1):2327
SimpsonGMAngusJWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand1970; 212(suppl):1119
14.
RobertsGWLeighPNWeinbergerDR. Neuropsychiatric disorders. St. Louis: Wolfe, 1993
15.
McKeithIFairbairnAPerryRNeuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ1992; 305: 673678
16.
SaitohTXiaYChenXThe CYP2D6B mutant allele is overrepresented in the Lewy body variant of Alzheimer's disease. Ann Neurol1995; 37: 110112
17.
ClaghornJHonigfeldGAbuzzahabPSThe risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol1987; 7: 377384
18.
PitnerJKMintzerJEPennypackerLCEfficacy and adverse effects of clozapine in four elderly psychotic patients. J Clin Psychiatry1995; 56: 180185
19.
JesteDVKrullAJ. Behavioral problems associated with dementia: diagnosis and treatment. Geriatrics1991; 46: 2834
20.
MillerCHMohrFUmbrichtDWoernerMThe prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone and conventional antipsychotics. J Clin Psychiatry1998; 59(2):6975
21.
KapurSRemingtonGZipurskyRBThe D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci1995; 57(10):PL103–PL107
22.
KatzIBrecherMClydeCRisperidone in the treatment of psychosis and aggressive behavior in patients with dementia. Presented at the 11th Annual Meeting of the American Association for Geriatric Psychiatry, San Diego, CA, March 8–11, 1998
23.
TariotPGaileSECastelliNAPonsteinssonAP. Treatment of agitation in dementia. N Dir Mental Health Serv1997; 76: 109123
24.
AllardPORinneJMarcussonJO. Dopamine uptake sites in Parkinson's disease and in dementia of the Alzheimer type. Brain Res1994; 637: 262266
25.
MorganDGMayPCFinchCE. Dopamine and serotonin systems in human and rodent brain: effects of age and neurodegenerative disease. J Am Geriatr Soc1987; 35: 334335
26.
PollockBGMulsantBHSweetRAn open pilot study of citalopram for behavioral disturbances of dementia. Am J Geriatr Psychiatry1997; 5: 7078
27.
TariotPNRosemaryEPodgorskiCAEfficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry1998; 155: 5461
28.
TariotPNSchneiderLSKatzIR. Anticonvulsant and other non-neuroleptic treatments of agitation in dementia. J Geriatr Psychiatry Neurol1995; 8(suppl 1):S28–S39
29.
ChambersCABainJRosbottomRCarbamazepine in senile dementia and overactivity—placebo controlled double-blind trial. IRCS Med Sci1982; 10: 505506
30.
TariotPNErbRLeiboviciACarbamazepine treatment of agitation in nursing home patients with dementia: a preliminary study. J Am Geriatr Soc1994; 42: 11601166
31.
CooneyCMortimerASmithACarbamazepine use in aggressive behavior associated with senile dementia. Int J Geriatr Psychiatry1996; 11: 901905
32.
HerrmannNLanctôtKL. From transmitters to treatment: the pharmacotherapy of behavioral disturbances in dementia. Can J Psychiatry1997; 42(suppl 1):51S–64S
33.
CatesMPowersR. Concomitant rash and blood dyscrasias in geriatric psychiatry patients treated with carbamazepine. Ann Pharmacother1998; 32: 884887
34.
LantzMSMarinD. Pharmacologic treatment of agitation in dementia: a comprehensive review. J Geriatr Psychiatry Neurol1996; 9: 107119
35.
MellowAMSolano-LopezCDavisS. Sodium valproate in the treatment of behavioral disturbance in dementia. J Geriatr Psychiatry Neurol1993; 6: 205209
36.
MazureCMDrussBGCellarJS. Valproate treatment of older psychotic patients with organic mental syndrome and behavioral dyscontrol. J Am Geriatr Soc1992; 40: 914916
37.
KunikMEPuryearLOrengoCAThe efficacy and tolerability of divalproex sodium in elderly demented patients with behavioral disturbances. Int J Geriatr Psychiatry1998; 13: 2934
38.
NarayanMNelsonJC. Treatment of dementia with behavioral disturbance using divalproex or a combination of divalproex and a neuroleptic. J Clin Psychiatry1997; 58: 351354
39.
SivalRCHaffmansPMHVanGertPPThe effects of sodium valproate on disturbed behaviour in dementia. J Geriatr Soc1994; 42: 906907
40.
HerrmannN. Valproic acid treatment of agitation in dementia. Can J Psychiatry1998; 43: 6972
41.
HaasSVincentKHoltJLippmannS. Divalproex; a possible treatment alternative for demented, elderly aggressive patients. Ann Clin Psychiatry1997; 9: 145147
42.
PorsteinssonAPTariotPNErbRAn open trial of valproate for agitation in geriatric neuropsychiatric disorders. Am J Geriatr Psychiatry1997; 5: 344351
43.
ChenCPAlderJTBowenDMPresynaptic serotonergic markers in community-aquired cases of Alzheimer's disease: correlations with depression and neuroleptic medication. J Neurochem1996; 66: 15921598
44.
CantillonMBrunswickRMolinaDBuspirone vs haloperidol: a double-blind trial for agitation in a nursing home population with Alzheimer'sdisease. Am J Geriatr Psychiatry1996; 4: 263271
45.
SteinbegJR. Anxiety in elderly patients. A comparison of azapirones and benzodiazepines. Drugs Aging1994; 5: 335345
46.
StrandMHettaJRosenAA double-blind controlled trial in primary care patients with generalized anxiety: a comparison between buspirone and oxazepam. J Clin Psychiatry1990; 51(suppl):4045
47.
SultzerDLGrayKFGunayIA double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Am J Geriatr Psychiatry1997; 5: 6069
48.
PollockBG. Drug interactions. In: NelsonJC ed. Geriatric psychopharmacology. New York: Marcel Dekker, 1998:4360
49.
PreskornSH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet1997; 32(suppl 1):121
50.
LiuBAMittmannNKnowlesSRHyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective reuptake inhibitors: a review of spontaneous reports. Can Med Assoc J1996; 155: 519527
51.
OlafssonKJorgensenSJensenHVFluvoxamine in the treatment of demented elderly patients: a double-blind, placebo-controlled study. Acta Psychiatr Scand1992; 85: 453456
52.
MulsantBHPollockBGRosenJ. New antidepressants and antipsychotics in the nursing home. Nurs Home Med1997; 5: 240248
53.
HyttelJ. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol1994; 9(suppl 1):1926
54.
NythALGottfriesCG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders: a Nordic multicentre study. Br J Psychiatry1990; 157: 894901
55.
GottfriesCG. Neurochemistry and neurotransmitters. Int Psychogeriatr1996; 8(suppl 3):225231
56.
VertainenHCitalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia. Acta Psychiatr Scand1995; 91: 348351
57.
SyvalahtiEKKallioniemiHLehtoH. Citalopram in patients with unsatisfactory response to neuroleptics: an open follow-up study. Methods Find Exp Clin Pharmacol1994; 16: 4955
58.
SalokangasRKSaarijarviSTaiminenTCitalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study. Acta Psychiatr Scand1996; 94: 175180
59.
GottfriesCG. Scandinavian experience with citalopram in the elderly. Int Clin Psychopharmacol1996; 11(suppl 1):4144
